Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Deffered Revenue (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $350.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue rose 5.06% to $350.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $350.1 million through Dec 2025, up 5.06% year-over-year, with the annual reading at $350.1 million for FY2025, 5.06% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $350.1 million at Phathom Pharmaceuticals, roughly flat from $349.0 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $350.1 million in Q4 2025, with the low at $109.5 million in Q4 2022.
  • Average Non-Current Deffered Revenue over 4 years is $276.8 million, with a median of $321.8 million recorded in 2024.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 173.74% in 2023, then increased 5.06% in 2025.
  • Over 4 years, Non-Current Deffered Revenue stood at $109.5 million in 2022, then soared by 173.74% to $299.8 million in 2023, then grew by 11.16% to $333.3 million in 2024, then grew by 5.06% to $350.1 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $350.1 million, $349.0 million, and $347.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.